Bagsværd, Denmark- September 2024- Novo Nordisk announced the presentation of 21 abstracts (7 oral and 14 short oral presentations) at the upcoming 60th Annual Meeting of the European Association for the Study of Diabetes (EASD), which will take place from 9 to 13 September 2024 in Madrid, Spain.
In addition to the abstracts, data will also be presented in dedicated scientific symposia. These include results from the COMBINE clinical programme with IcoSema, a combination of once-weekly basal insulin icodec and once-weekly semaglutide, in people with type 2 diabetes, the FLOW trial evaluating semaglutide 1.0 mg on kidney outcomes in people with type 2 diabetes and chronic kidney disease, and amylin treatment for metabolic disease.
Also Read: Dose Check: Your Personalized Insulin Coach
“Cardiometabolic conditions like diabetes, obesity, cardiovascular and kidney disease, all result from closely interlinked underlying risk factors and are among the most significant health challenges society faces today. Tailored treatment options that aim to holistically address these conditions are therefore needed,” said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “At EASD this year, we are showcasing new data from across our diabetes, obesity, cardiovascular and renal pipeline and portfolio, where we continue to push boundaries with the goal of advancing treatments in order to help more patients.”
Summary of presentations
Accepted data at the 60th annual meeting of the EASD include the following oral and short oral presentations. Accepted abstracts include preliminary data that may be subject to change in final published manuscripts. Dates and times of the presentations and the abstracts can be found on the EASD website.
